Search - tctmd.com

Displaying 101 - 120 of 196

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2016

Shelley Wood

May 31, 2016

News Conference News EuroPCR 2016

Reassuring Registry Data Suggest Scaffold Thrombosis Rates with BVS Declining

Michael O'Riordan

May 17, 2016

News Daily News

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Michael O'Riordan

March 30, 2016

News Daily News

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

Michael O'Riordan

March 30, 2016

Presentation

1-Year Outcomes With Absorb BVS: Patient-Level, Pooled Meta-Analysis

Presenter: Gregg Stone

March 29, 2016

News Daily News

FDA 专家小组对 Absorb 生物可吸收支架呈压倒性支持

Michael O'Riordan

March 16, 2016

News Daily News

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

Michael O'Riordan

March 16, 2016

News Daily News

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Michael O'Riordan

March 14, 2016

News Daily News

生物可吸收支架导致装置血栓风险增加，但一些人士表示风险可得到抑制

Michael O'Riordan

February 23, 2016

News Daily News

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Michael O'Riordan

February 23, 2016

Presentation JIM 2016

ABSORB BVS:What Have we Learned?

Presenter: Gregg W. Stone

February 09, 2016

News Daily News

Bioresorbable Scaffolds May Have Role in Spontaneous Coronary Artery Dissections

Todd Neale

December 30, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Presenter: Stephen G. Ellis, Patrick W. Serruys, Davide Capodanno

October 14, 2015

Presentation TCT 2015

TCT 13: Clinical Outcomes After Implantation of Absorb BVS in Small Vessels Results From the Italian RAI Multicenter Registry

Presenter: Stephen G. Ellis, Lorenz Raber, Giulia Masiero

October 13, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

Advertisement

TCTMD’s Top 10 Most Popular Stories for May 2016

Reassuring Registry Data Suggest Scaffold Thrombosis Rates with BVS Declining

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Absorb BVS：两项新研究解决了安全性、有效性和支架血栓问题

1-Year Outcomes With Absorb BVS: Patient-Level, Pooled Meta-Analysis

FDA 专家小组对 Absorb 生物可吸收支架呈压倒性支持

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

生物可吸收支架导致装置血栓风险增加，但一些人士表示风险可得到抑制

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

ABSORB BVS:What Have we Learned?

Bioresorbable Scaffolds May Have Role in Spontaneous Coronary Artery Dissections

My Takeaways From TCT 2015

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

TCT 13: Clinical Outcomes After Implantation of Absorb BVS in Small Vessels Results From the Italian RAI Multicenter Registry

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content